New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice

Amgen (NASDAQ:AMGN) today announced results from an integrated
analysis showing primary prophylactic use of Neulasta(R)
(pegfilgrastim), a granulocyte colony stimulating factor (G-CSF), with
unique neutrophil-mediated clearance, decreased febrile-neutropenia
(FN) hospitalizations by more than half (4 percent vs. 10 percent)
when compared to current practice neutropenia management and reduced
chemotherapy dose reductions by nearly two-thirds (9 percent vs. 24
percent). The results were presented as an oral presentation at the
14th European Cancer Conference (ECCO) in Barcelona, Spain (Abstract #
2.033).

"Febrile neutropenia, or a low white blood cell count accompanied
by fever, is one of the most serious adverse events related to
myelosuppressive chemotherapy and is still a common cause of
hospitalizations and associated infection-related deaths," said G. Von
Minckwitz, M.D., Ph.D., University of Frankfurt, German Breast Group
GBG Forschungs GmbH, Frankfurt, Germany. "These study findings
emphasize the benefits of primary prophylactic use of Neulasta."

In this integrated analysis of 2,282 breast cancer patients, 9
percent of patients who received primary prophylaxis with Neulasta had
chemotherapy dose reductions compared to 24 percent of patients who
received current practice neutropenia management. Additionally, the
analysis showed that prophylactic use of Neulasta resulted in 4
percent FN hospitalizations versus 10 percent for current practice.
The results presented today expand on the positive outcomes from the
same study first presented at American Society of Clinical Oncology
(ASCO) Breast Symposium in San Francisco earlier this month, which
showed that primary prophylaxis with Neulasta significantly reduced
the incidence of FN compared to current neutropenia management (five
percent vs. 29 percent).

An abnormally low white blood cell count can be serious because
the body's ability to fight off infections becomes impaired, and even
a minor infection can become life-threatening. Importantly,
neutropenia is the major dose-limiting side effect of myelosuppressive
chemotherapy and is the primary reason for chemotherapy dose delays
and reductions. Current European Organization for Research and
Treatment (EORTC), National Comprehensive Cancer Network (NCCN), and
ASCO neutropenia guidelines recommend routine growth factor primary
prophylaxis for patients with an overall FN risk greater than or equal
to 20 percent.

About the Analysis

For this integrated analysis, studies involving breast cancer
chemotherapy regimens with moderate (15-20 percent)/high (greater than
or equal to 20 percent) risk of febrile neutropenia were identified by
literature review. Individual patient data were available from eight
clinical trials and three observational studies (conducted between
1998 and 2005) involving these regimens and primary prophylactic use
of Neulasta (6 mg dose in all cycles) or current practice neutropenia
management (defined as no G-CSF or pegfilgrastim / daily G-CSF in any
cycle). Of the 2,282 patients analyzed, 1,303 received Neulasta as
primary prophylaxis and 979 were treated based on current practice.

About Neulasta

Neulasta is approved to decrease the incidence of infection, as
manifested by febrile neutropenia, in patients with non-myeloid
malignancies receiving myelosuppressive anticancer drugs associated
with a clinically significant incidence of febrile neutropenia.
Similar indications for Neulasta were approved in Europe and Australia
in 2002.

Important Product Safety Information

Splenic rupture (including fatal cases), acute respiratory
distress syndrome, and sickle cell crises have been reported. Allergic
reactions, including anaphylaxis, have also been reported. The
majority of these reactions occurred upon initial exposure. However,
in rare cases, allergic reactions, including anaphylaxis, recurred
within days after discontinuing antiallergic treatment.

In a placebo-controlled trial, bone pain occurred at a higher
incidence in Neulasta-treated patients as compared to placebo-treated
patients (31 percent vs. 26 percent). The most common adverse events
reported in either placebo- or active-controlled trials were
consistent with the underlying cancer diagnosis and its treatment with
chemotherapy, with the exception of bone pain.

Prescribers are recommended to consult regional prescribing
information before prescribing Neulasta, particularly in relation to
side-effects, precautions and contra-indications.

About Amgen

Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis and other serious illnesses. With
a deep and broad pipeline of potential new medicines, Amgen remains
committed to advancing science to dramatically improve people's lives.
To learn more about our pioneering science and our vital medicines,
visit www.amgen.com.

Forward-Looking Statements

This news release contains forward-looking statements that are
based on management's current expectations and beliefs and are subject
to a number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described. All
statements, other than statements of historical fact, are statements
that could be deemed forward-looking statements, including estimates
of revenues, operating margins, capital expenditures, cash, other
financial metrics, expected legal, arbitration, political, regulatory
or clinical results or practices, customer and prescriber patterns or
practices, reimbursement activities and outcomes and other such
estimates and results. Forward-looking statements involve significant
risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC)
reports filed by Amgen, including Amgen's most recent annual report on
Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.
Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for
additional information on the uncertainties and risk factors related
to our business. Unless otherwise noted, Amgen is providing this
information as of Sept. 25, 2007, and expressly disclaims any duty to
update information contained in this news release.

No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe
and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modeled by computer or cell culture systems or animal
models. The length of time that it takes for us to complete clinical
trials and obtain regulatory approval for product marketing has in the
past varied and we expect similar variability in the future. We
develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates
that are derived from relationships may be subject to disputes between
the parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also, we
or others could identify safety, side effects or manufacturing
problems with our products after they are on the market. Our business
may be impacted by government investigations, litigation and products
liability claims. We depend on third parties for a significant portion
of our manufacturing capacity for the supply of certain of our current
and future products and limits on supply may constrain sales of
certain of our current products and product candidate development.

In addition, sales of our products are affected by the
reimbursement policies imposed by third-party payors, including
governments, private insurance plans and managed care providers and
may be affected by regulatory, clinical and guideline developments and
domestic and international trends toward managed care and health care
cost containment as well as U.S. legislation affecting pharmaceutical
pricing and reimbursement. Government and others' regulations and
reimbursement policies may affect the development, usage and pricing
of our products. In addition, we compete with other companies with
respect to some of our marketed products as well as for the discovery
and development of new products. We believe that some of our newer
products, product candidates or new indications for existing products,
may face competition when and as they are approved and marketed. Our
products may compete against products that have lower prices,
established reimbursement, superior performance, are easier to
administer, or that are otherwise competitive with our products. In
addition, while we routinely obtain patents for our products and
technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors and there can be no guarantee of our ability to obtain or
maintain patent protection for our products or product candidates. We
cannot guarantee that we will be able to produce commercially
successful products or maintain the commercial success of our existing
products. Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of
our products or product candidates. Further, the discovery of
significant problems with a product similar to one of our products
that implicate an entire class of products could have a material
adverse effect on sales of the affected products and on our business
and results of operations.

The scientific information discussed in this news release related
to our product candidates is preliminary and investigative. Such
product candidates are not approved by the U.S. Food and Drug
Administration (FDA) or European Medicines Agency (EMEA), and no
conclusions can or should be drawn regarding the safety or
effectiveness of the product candidates. Only the FDA, EMEA or
comparable regulatory body can determine whether the product
candidates are safe and effective for the use(s) being investigated.
Further, the scientific information discussed in this news release
relating to new indications for our products is preliminary and
investigative and is not part of the labeling approved by the FDA or
EMEA for the products. The products are not approved for
the investigational use(s) discussed in this news release, and no
conclusions can or should be drawn regarding the safety or
effectiveness of the products for these uses. Only the FDA, EMEA or
comparable regulatory body can determine whether the products are safe
and effective for these uses. Healthcare professionals should refer to
and rely upon the applicable FDA- or EMEA-approved labeling for the
products, and not the information discussed in this news release.